Applied Therapeutics Inc. (APLT)
0.64
-0.05 (-7.38%)
At close: Jan 14, 2025, 3:59 PM
0.66
3.06%
Pre-market Jan 15, 2025, 06:49 AM EST
undefined% (undefined)
| Bid | 0.64 |
| Market Cap | 74.43M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -1.42 |
| PE Ratio (ttm) | -0.45 |
| Forward PE | n/a |
| Analyst | Hold |
| Ask | 0.67 |
| Volume | 8,142,045 |
| Avg. Volume (20D) | 6,288,604 |
| Open | 0.70 |
| Previous Close | 0.69 |
| Day's Range | 0.62 - 0.73 |
| 52-Week Range | 0.60 - 10.62 |
| Beta | undefined |
About APLT
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase 1/2 for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the...
Industry Biotechnology
Sector Healthcare
IPO Date May 14, 2019
Employees 37
Stock Exchange NASDAQ
Ticker Symbol APLT
Analyst Forecast
According to 6 analyst ratings, the average rating for APLT stock is "Hold." The 12-month stock price forecast is $5, which is an increase of 681.62% from the latest price.
Buy 50.00%
Hold 50.00%
Sell 0.00%
Next Earnings Release
Applied Therapeutics Inc. is scheduled to release its earnings on Mar 5, 2025,
before market opens.
Analysts project revenue of $183.33K, reflecting a -127.49% YoY shrinking and earnings per share of -0.17, making a -57.50% decrease YoY.
Analysts project revenue of $183.33K, reflecting a -127.49% YoY shrinking and earnings per share of -0.17, making a -57.50% decrease YoY.
3 weeks ago ·
Source
-13.72%
Applied Therapeutics shares are trading lower afte...
Unlock content with
Pro Subscription
1 month ago ·
Source
-13.79%
Applied Therapeutics shares are trading lower after UBS downgraded the stock from Buy to Neutral and cut its price target from $13 to $2.
